Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,575Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M145EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book5.110-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.4PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M39,300,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with XBI

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
XBIFirst Eagle Investment 2016-03-31 Buy $45.73 - $70.2
$ 65.5226%New holding18,150
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XBI is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

XBI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Keogh, WillemSenior Officer 2016-09-08Buy338$21.28207.89view
Sardo, Vincent JamesDirector 2016-09-08Sell1,500$43.0552.2view
Larson, Douglas RobertDirector, Senior Officer 2016-09-08Sell800$8.35684.67view
Fraser, AlisonDirector or Senior Officer of Insider or Subsidiar 2016-09-08Sell12,700$10.18543.61view
Brown, ArthurDirector 2016-09-08Sell250,000$0.0793500view
Brewster, NormanSenior Officer 2016-09-08Sell45,000$0.03218300view
Darling, Neil B.T.Director 2016-09-08Buy53,500$0.2724166.67view
Porter, Brian JDirector, Senior Officer 2016-09-08Sell25,176$70.17-6.63view
Marsh, John M.Director 2016-09-08Sell36,000$29.5122.1view
Graham, Eric JohnSenior Officer 2016-09-08Buy1,700$3.231928.48view

Quarterly/Annual Reports about XBI:

    News about XBI:

    Articles On GuruFocus.com
    Value Investing in BioPharma Nov 18 2015 
    Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

    More From Other Websites
    Expect More Volatility for Healthcare ETFs Sep 27 2016
    [$$] Biotech Is Cheaper Than Big Pharma Sep 24 2016
    Gilead Sciences: Another Blow to R&D Strategy Sep 22 2016
    Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain Sep 21 2016
    Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment Sep 21 2016
    Biotech ETF At Best Level Since January; Are You Braced For Bumps? Sep 20 2016
    How Ionis’s Revenue Trends Are Changing Sep 20 2016
    Charting the S&P 500’s bullish-leaning holding pattern ahead of the Fed Sep 20 2016
    Tuesday links: personal well-being Sep 20 2016
    The Week Ahead: Should You Care About The 'Bulls No.1 Lie?' Sep 17 2016
    A Battered Biotech ETF can Rise Again Sep 16 2016
    Biotech bright spots Sep 15 2016
    A Good Trader Should Be Able to Adjust to Changing Markets Sep 14 2016
    Inside the Recent Surge in Biotech ETFs Sep 14 2016
    Applied Genetics’ stock suffers record plunge to record low Sep 13 2016
    3 Reasons to Buy Teva Right Now Sep 13 2016
    Biotech ETFs: Rallying Because Hillary Clinton Has Pneumonia? Sep 12 2016
    Here Are the Latest Analyst Recommendations for Biogen Sep 09 2016
    Understanding Incyte’s Revenue Stream in 2Q16 Sep 02 2016
    Clinton's Proposal To Combat Drug Price Hikes Sep 02 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)